Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Esophageal Perforation-I: Introduction01:22

Esophageal Perforation-I: Introduction

Esophageal perforation is a severe medical condition characterized by a breach in the integrity of the esophageal wall. This breach can occur due to various factors such as trauma, medical procedures, or underlying diseases. When the esophageal wall is compromised, it allows food, fluids, and digestive juices into the chest cavity or adjacent structures, leading to potential complications and health risks.
The location of esophageal perforation can vary, occurring anywhere along the esophagus.
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Esophageal Perforation-II: Clinical Manifestations and Management01:28

Esophageal Perforation-II: Clinical Manifestations and Management

Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Esophageal Varices-I: Introduction01:24

Esophageal Varices-I: Introduction

Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.

International journal of clinical oncology·2026
Same author

[A Case of Hepatic Oligometastasis from Distal Bile Duct Cancer Treated with Laparoscopic Surgery Five Years after Pancreatoduodenectomy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same author

Impact of Distributing Test Result Reports for Chronic Viral Hepatitis on Awareness of Hepatitis Testing Among Non-Specialist Physicians.

Medicina (Kaunas, Lithuania)·2025
Same author

Efficacy of liquid biopsy in colorectal cancer.

Journal of gastrointestinal oncology·2025
Same author

Prediction of long-term recurrence-free and overall survival in early-onset colorectal cancer: the ENCORE multi-centre study.

NPJ precision oncology·2025
Same author

The Current Status of Adjuvant Chemotherapy for Colorectal Cancer in Japan: A Paradigm Shift from Oral Fluoropyridine Single Therapy to the Oxaliplatin Regimen.

Cancers·2025

Related Experiment Video

Updated: Jun 28, 2026

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography
06:44

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography

Published on: April 13, 2018

[Venous thrombosis and bowel perforation].

Hiroyuki Uetake1, Toshiaki Ishikawa, Kenichi Sugihara

  • 1Department of Translational Oncology, Tokyo Medical and Dental Universty, Tokyo, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 22, 2008
PubMed
Summary

Bevacizumab in cancer therapy can cause thrombosis, a serious complication. Low-molecular weight heparin is recommended for treatment, with careful consideration for wound healing delays.

Area of Science:

  • Oncology
  • Vascular Medicine
  • Pharmacology

Context:

  • Cancer chemotherapy regimens, particularly those involving bevacizumab (Bmab), are associated with significant risks of arterial and venous thrombosis.
  • Established guidelines, such as those from ASCO for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer, recommend low-molecular weight heparin (LMWH) for managing venous thrombosis.
  • The management of these thromboembolic events requires careful consideration of potential complications like bowel perforation and the impact of Bmab on wound healing.

Purpose:

  • To review the complications associated with bevacizumab administration during cancer chemotherapy, focusing on thromboembolic events.
  • To highlight the recommended treatment strategies for venous thrombosis in cancer patients receiving bevacizumab.
  • To emphasize the importance of considering wound healing delays in the management of patients experiencing bevacizumab-related complications.

More Related Videos

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products
14:54

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products

Published on: October 20, 2018

Related Experiment Videos

Last Updated: Jun 28, 2026

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography
06:44

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography

Published on: April 13, 2018

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products
14:54

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products

Published on: October 20, 2018

Summary:

  • Bevacizumab (Bmab) administration in cancer chemotherapy can lead to serious arterial and venous thrombosis.
  • Low-molecular weight heparin (LMWH) is the recommended treatment for venous thrombosis in these patients, with full-dose anticoagulation not increasing bleeding risk.
  • Management must account for potential complications like bowel perforation and bevacizumab-induced wound healing delays.

Impact:

  • Informs oncologists and healthcare providers about the thrombotic risks associated with bevacizumab.
  • Provides guidance on the appropriate use of low-molecular weight heparin for managing venous thromboembolism in cancer patients.
  • Underscores the need for a multidisciplinary approach to manage complex complications, including surgical interventions and wound care considerations.